“Establishing world-class manufacturing capability has always been a priority for Kite,” said Timothy Moore, Kite’s Executive Vice President of Technical Operations.
The plant’s location, adjacent to Los Angeles International Airport, is intended to expedite receipt and shipment of engineered T-cells from and to patients across the United States and Europe. The facility is estimated to have the capacity to produce up to 5,000 patient therapies per year. Kite anticipates commercial launch of KTE-C19 in 2017. The facility has been designed to produce chimeric antigen receptor (CAR) and T-cell receptor (TCR) product candidates for clinical trials, as well as for the potential launch and commercialization of Kite’s lead CAR T-cell product candidate, KTE-C19, which is in clinical study for the treatment of chemorefractory diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. Over 300 employees, investors and company partners attended the unveiling of the 43,500-square-foot, state-of-the-art plant. Kite Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing engineered autologous T-cell therapy (eACT™) products for the treatment of cancer, opened a new commercial manufacturing facility in El Segundo, California.
0 kommentar(er)
